Overview

This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.

Eligibility

Inclusion Criteria:

1. Male or female ≥ 18 years of age
2. Recipient of their first kidney transplant from a living or deceased donor
3. Agree to comply with contraception requirements during and for at least 90 days after the last administration of study drug

Exclusion Criteria:

1. Induction therapy, other than study assigned rATG, planned as part of initial immunosuppressive regimen
2. Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies, with the exception of 5 mg prednisone or equivalent daily;
3. Previous treatment with AT 1501 or any other anti CD40LG therapy
4. The patient has previously received a bone marrow transplant or any other solid organ transplant, including a kidney, or will be undergoing a multi organ or dual kidney transplant
5. Will receive a kidney with an anticipated cold ischemia time of > 30 hours;
6. Will receive a kidney from a donor that meets any of the following:

   • Donation after Cardiac Death (DCD) criteria; or

   Extended Criteria Donor (ECD) criteria, defined as:

   • Is blood group (ABO) incompatible; or
   • Age ≥ 60 years; or
   • Age 50-59 years with any 2 of the following criteria
   • Death due to cerebrovascular accident
   • History of hypertension
   • Terminal creatinine ≥ 133 μmol/L
7. Human leukocyte antigen identical (two haplotype match or zero HLA mismatch) donor
8. Medical conditions that require chronic use of systemic steroids at a dose higher than 5 mg prednisone or equivalent per day
9. History of a TE event, known hypercoagulable state, or condition requiring long term

   anticoagulation

   1. Patients with a history of clotted venous access not requiring long term anticoagulation may be included at the Investigator's discretion if have no other history of TE events or known hypercoagulable state